Relypsa Company Profile (NASDAQ:RLYP)

About Relypsa

Relypsa logoRelypsa, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of polymer-based drugs to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patients' lives and even be life-threatening. The Company's first drug candidate is Veltassa (patiromer) for oral suspension, or Veltassa, for the treatment of hyperkalemia. Hyperkalemia is a life threatening condition defined as abnormally elevated levels of potassium in the blood. Veltassa is a non-absorbed, potassium binding polymer. The active ingredient in Veltassa is a cross-linked polymeric bead that includes calcium as a counterion. Veltassa is a dry powder that is combined with small amounts of water prior to administration. Veltassa is packaged in single-use packets containing approximately 8.4 grams, 16.8 grams or 25.2 grams patiromer, with a recommended starting dose of approximately 8.4 grams patiromer once daily.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RLYP
  • CUSIP:
Key Metrics:
  • Previous Close: $31.99
  • 50 Day Moving Average: $30.31
  • 200 Day Moving Average: $20.28
  • 52-Week Range: $10.26 - $32.12
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.13
  • P/E Growth: 0.00
  • Market Cap: $N/A
  • Beta: 2.19
Additional Links:
Companies Related to Relypsa:

Analyst Ratings

Consensus Ratings for Relypsa (NASDAQ:RLYP) (?)
Ratings Breakdown: 10 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $36.23 (13.26% upside)

Analysts' Ratings History for Relypsa (NASDAQ:RLYP)
DateFirmActionRatingPrice TargetDetails
9/1/2016BTIG ResearchDowngradeBuy -> NeutralView Rating Details
9/1/2016WedbushDowngradeOutperform -> Neutral$32.00View Rating Details
8/22/2016Stifel NicolausDowngradeBuy -> Hold$32.00View Rating Details
8/13/2016MizuhoReiterated RatingNeutral$32.00View Rating Details
8/8/2016Cantor FitzgeraldReiterated RatingHold$32.00View Rating Details
7/22/2016HC WainwrightDowngradeBuy -> Neutral$32.00View Rating Details
7/21/2016Morgan StanleyUpgradeUnderweight -> Equal Weight$9.00 -> $32.00View Rating Details
7/21/2016Citigroup Inc.DowngradeBuy -> Neutral$25.00 -> $32.00View Rating Details
7/21/2016Brean CapitalDowngradeBuy -> HoldView Rating Details
5/31/2016Oppenheimer Holdings Inc.Reiterated RatingOutperform$36.00View Rating Details
5/29/2016Cowen and CompanyReiterated RatingBuyView Rating Details
4/1/2016Raymond James Financial Inc.Initiated CoverageMarket PerformView Rating Details
2/25/2016Bank of America Corp.Reiterated RatingBuy$32.00 -> $29.00View Rating Details
11/4/2015GuggenheimInitiated CoverageBuy$46.00View Rating Details
10/27/2015NomuraReiterated RatingOutperform$75.00View Rating Details
(Data available from 10/26/2014 forward)


Earnings History for Relypsa (NASDAQ:RLYP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q2($1.56)($1.87)$5.45 million$5.22 millionViewN/AView Earnings Details
5/4/2016Q1($1.46)($1.26)$6.88 million$12.40 millionViewListenView Earnings Details
2/24/2016Q415($1.35)($1.40)$7.37 million$11.96 millionViewListenView Earnings Details
11/4/2015Q3($0.89)($1.24)$6.67 million$6.50 millionViewN/AView Earnings Details
8/6/2015($0.95)($0.95)$0.01 millionViewN/AView Earnings Details
5/7/2015($0.87)($0.78)ViewN/AView Earnings Details
3/11/2015Q414($0.68)($0.80)ViewN/AView Earnings Details
11/10/2014($0.61)($0.57)ViewN/AView Earnings Details
8/11/2014($0.57)($0.51)ViewN/AView Earnings Details
5/7/2014($0.56)($0.54)ViewN/AView Earnings Details
3/17/2014Q413($0.50)($0.68)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Relypsa (NASDAQ:RLYP)
Current Year EPS Consensus Estimate: $-6.33 EPS
Next Year EPS Consensus Estimate: $-6.24 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($1.61)($1.42)($1.52)
Q2 20162($1.53)($1.43)($1.48)
Q3 20162($1.65)($1.47)($1.56)
Q4 20162($1.65)($1.40)($1.53)
Q1 20171($1.65)($1.65)($1.65)
Q2 20171($1.64)($1.64)($1.64)
Q3 20171($1.62)($1.62)($1.62)
Q4 20171($1.59)($1.59)($1.59)
(Data provided by Zacks Investment Research)


Dividend History for Relypsa (NASDAQ:RLYP)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Relypsa (NASDAQ:RLYP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/17/2016James D DonderoMajor ShareholderBuy500$31.92$15,960.00View SEC Filing  
8/16/2016Monte MontgomeryInsiderSell510$31.92$16,279.20View SEC Filing  
8/11/2016James D DonderoMajor ShareholderSell37,000$31.96$1,182,520.00View SEC Filing  
7/25/2016Orbimed Advisors LlcMajor ShareholderSell4,043,600$32.00$129,395,200.00View SEC Filing  
6/7/2016David W J McgirrDirectorSell1,013$19.34$19,591.42View SEC Filing  
3/16/2016Kristine M BallCFOBuy7,000$12.15$85,050.00View SEC Filing  
3/15/2016Thomas J SchuetzDirectorBuy30,000$13.39$401,700.00View SEC Filing  
12/31/2015Wilhelm StahlSVPSell20,000$28.53$570,600.00View SEC Filing  
12/23/2015Orbimed Advisors LlcMajor ShareholderSell500,000$27.18$13,590,000.00View SEC Filing  
12/9/2015Lance BermanSVPSell750$29.50$22,125.00View SEC Filing  
12/7/2015John A. OrwinCEOSell15,000$28.28$424,200.00View SEC Filing  
12/7/2015Lance BermanSVPSell30,000$29.78$893,400.00View SEC Filing  
12/4/2015John A. OrwinCEOSell40,000$25.00$1,000,000.00View SEC Filing  
10/22/2015Orbimed Advisors LlcMajor ShareholderBuy500,000$12.56$6,280,000.00View SEC Filing  
8/17/2015John A OrwinCEOSell5,000$24.84$124,200.00View SEC Filing  
8/17/2015Lance BermanSVPSell710$24.77$17,586.70View SEC Filing  
8/17/2015Ronald A KrasnowInsiderSell522$24.75$12,919.50View SEC Filing  
6/11/2015Thomas J SchuetzDirectorSell1,000$34.57$34,570.00View SEC Filing  
6/1/2015John A OrwinCEOSell33,555$36.42$1,222,073.10View SEC Filing  
5/18/2015Orbimed Advisors LlcMajor ShareholderSell1,457,551$34.13$49,746,215.63View SEC Filing  
5/11/2015Klaus R Dr VeitingerDirectorSell5,834$36.06$210,374.04View SEC Filing  
4/10/2015Klaus R Dr VeitingerDirectorSell5,832$35.35$206,161.20View SEC Filing  
3/5/2015Kristine M BallCFOSell3,519$40.68$143,152.92View SEC Filing  
2/27/2015Ronald A KrasnowInsiderSell10,348$39.00$403,572.00View SEC Filing  
2/24/2015Lance BermanSVPSell5,000$38.19$190,950.00View SEC Filing  
2/24/2015Ronald A KrasnowInsiderSell10,000$39.00$390,000.00View SEC Filing  
2/10/2015Klaus R Dr VeitingerDirectorSell5,834$32.12$187,388.08View SEC Filing  
1/21/2015Claire LockeyInsiderSell5,000$35.00$175,000.00View SEC Filing  
1/21/2015Kristine M BallCFOSell3,000$36.00$108,000.00View SEC Filing  
1/14/2015Ronald A KrasnowInsiderSell5,000$33.58$167,900.00View SEC Filing  
1/12/2015Klaus R Dr VeitingerDirectorSell5,834$32.33$188,613.22View SEC Filing  
12/12/2014Klaus R Dr VeitingerDirectorSell14,169$32.16$455,675.04View SEC Filing  
12/9/20145Am Partners Iii, LlcMajor ShareholderSell589,637$30.04$17,712,695.48View SEC Filing  
12/9/2014Claire LockeyInsiderSell8,000$30.00$240,000.00View SEC Filing  
11/25/2014Lance BermanSVPSell30,000$25.00$750,000.00View SEC Filing  
10/10/2014Klaus R Dr VeitingerDirectorSell2,500$19.34$48,350.00View SEC Filing  
9/24/2014Lance BermanSVPSell5,000$22.00$110,000.00View SEC Filing  
9/17/2014Orbimed Advisors LlcMajor ShareholderSell94,000$25.27$2,375,380.00View SEC Filing  
9/16/20145Am Partners Ii, LlcMajor ShareholderSell612,540$26.03$15,944,416.20View SEC Filing  
9/10/2014Klaus R Dr VeitingerDirectorSell4,167$23.00$95,841.00View SEC Filing  
8/29/2014Wilhelm StahlSVPSell15,785$25.29$399,202.65View SEC Filing  
8/26/20145Am Partners Ii, LlcMajor ShareholderSell433,000$26.51$11,478,830.00View SEC Filing  
8/25/2014Lance BermanSVPSell20,000$25.89$517,800.00View SEC Filing  
8/11/2014Klaus R Dr VeitingerDirectorSell4,167$27.73$115,550.91View SEC Filing  
7/24/2014Lance BermanSVPSell45,000$23.92$1,076,400.00View SEC Filing  
7/10/2014Klaus R Dr VeitingerDirectorSell4,167$23.12$96,341.04View SEC Filing  
11/20/20135Am Partners Iii, LlcMajor ShareholderBuy372,692$11.00$4,099,612.00View SEC Filing  
11/20/2013John A OrwinCEOBuy15,000$11.00$165,000.00View SEC Filing  
11/20/2013Leaf Ventures I L.P. NewInsiderBuy185,978$11.00$2,045,758.00View SEC Filing  
11/20/2013Scott M RocklageDirectorBuy363,328$11.00$3,996,608.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Relypsa (NASDAQ:RLYP)
News IconRelypsa, Inc. (NASDAQ:RLYP) Updated Broker Price Targets - The De Soto Edge (NASDAQ:RLYP) - October 26 at 10:37 AM
News Icon675 Shares of Relypsa Inc. (RLYP) are sold by Tocqueville Asset Management LP - DailyQuint (NASDAQ:RLYP) - October 26 at 10:37 AM
News IconLatest Analyst Reports On Relypsa, Inc. - NewsDen (NASDAQ:RLYP) - October 20 at 8:33 AM
News IconCapital Fund Management SA Acquires New Stake in Relypsa Inc. (RLYP) - DailyQuint (NASDAQ:RLYP) - October 15 at 6:39 PM
News IconRatings Don't Lie: Were Analysts Bearish Relypsa Inc (NASDAQ:RLYP) This Week? - MoneyMakingArticles (NASDAQ:RLYP) - October 12 at 12:33 PM
News IconRelypsa, Inc. (NASDAQ:RLYP) Updated Analyst Coverage - NewsDen (NASDAQ:RLYP) - October 10 at 6:35 PM
News IconBroker Roundup For Relypsa, Inc. (NASDAQ:RLYP) - The De Soto Edge (NASDAQ:RLYP) - September 30 at 3:36 PM
News IconWedbush Reaffirms “Buy” Rating for Relypsa Inc (RLYP) - DailyQuint (NASDAQ:RLYP) - September 20 at 12:22 PM logoRelypsa Inc (RLYP) Downgraded To A Neutral At Wedbush; Here's Why (NASDAQ:RLYP) - September 4 at 11:06 AM logoRelypsa Inc (RLYP) Downgraded To A Neutral At Wedbush; Here's Why - TCC (NASDAQ:RLYP) - September 2 at 6:57 PM logoGalenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies (NASDAQ:RLYP) - September 2 at 11:59 AM logoSome clouds might have a silver lining, according to Wedbush (NASDAQ:RLYP) - September 1 at 7:01 PM logoGalenica Announces 85.6% of Relypsa (RLYP) Shares Have Been Tendered (NASDAQ:RLYP) - September 1 at 7:01 PM
News IconTraders Alert: Ross Stores, Inc. (NASDAQ:ROST), Relypsa Inc (NASDAQ:RLYP), International Game Technology ... - NYSE Journal (press release) (NASDAQ:RLYP) - September 1 at 10:13 AM
News IconIntraday Active Biotech Stocks News: Northwest Biotherapeutics, Inc. (NASDAQ:NWBO), Relypsa, Inc. (NASDAQ:RLYP) - The Voice Registrar (NASDAQ:RLYP) - September 1 at 10:13 AM logoGalenica announces Expiration of Cash Tender Offer for Shares of Common Stock of Relypsa (NASDAQ:RLYP) - September 1 at 10:13 AM logoRELYPSA INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Triggering Events That Accelerate or (NASDAQ:RLYP) - September 1 at 10:13 AM
News IconBiotech Stocks Worth a Closer Look: Relypsa, Inc. (NASDAQ:RLYP), Intrexon Corporation (NYSE:XON) - The Voice Registrar (NASDAQ:RLYP) - August 31 at 12:20 PM logoRelypsa downgraded by Stifel (NASDAQ:RLYP) - August 30 at 7:00 PM logo4:05 pm Relypsa announces that the Phase 4 TOURMALINE study, which evaluated the efficacy and safety of Veltassa for oral suspension with or without food for the treatment of hyperkalemia, met its primary endpoint (NASDAQ:RLYP) - August 30 at 7:00 PM logoRelypsa Announces Phase 4 Study Shows Veltassa® Demonstrated Similar Efficacy and Safety Whether Given With or Without Food in Patients with Hyperkalemia (NASDAQ:RLYP) - August 30 at 7:00 PM
News IconHC Stocks Growth: Zoetis Inc (ZTS), Relypsa Inc (NASDAQ:RLYP) - share market updates (press release) (NASDAQ:RLYP) - August 30 at 10:23 AM
News IconHot Biotech Stocks Recap: Relypsa, Inc. (NASDAQ:RLYP), Heat Biologics, Inc. (NASDAQ:HTBX) - The Voice Registrar (NASDAQ:RLYP) - August 30 at 10:23 AM
News IconInvestor News: Lawsuit against Buyout of Relypsa Inc (NASDAQ:RLYP) filed (NASDAQ:RLYP) - August 29 at 11:42 AM
News IconTrading the Biotech News: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Relypsa, Inc. (NASDAQ:RLYP) - The Voice Registrar (NASDAQ:RLYP) - August 26 at 10:05 AM
News Icon2 Biotech Stocks News And Price Trends: Relypsa, Inc. (NASDAQ:RLYP), Juno Therapeutics Inc. (NASDAQ:JUNO) - The Voice Registrar (NASDAQ:RLYP) - August 24 at 6:52 PM
News IconOverbuying Stock in Spotlight: Relypsa Inc (NASDAQ:RLYP) - Post Registrar (NASDAQ:RLYP) - August 24 at 6:52 PM logoLawsuit for Investors in Relypsa Inc (NASDAQ:RLYP) in Effort to Halt the Takeover by Galenica Group (NASDAQ:RLYP) - August 22 at 7:03 PM
News IconNoteworthy Insider Trading: Relypsa Inc (RLYP) - The Voice Registrar (NASDAQ:RLYP) - August 20 at 11:08 AM
News IconBiotech news that matter for investors: Relypsa, Inc. (NASDAQ:RLYP), Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - The Voice Registrar (NASDAQ:RLYP) - August 18 at 10:09 AM
News IconHC Stocks Outlines: Relypsa Inc (NASDAQ:RLYP), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) - share market updates (press release) (NASDAQ:RLYP) - August 18 at 10:09 AM
News IconInsider Trading in Focus: Relypsa Inc (NASDAQ:RLYP) - Post Registrar (NASDAQ:RLYP) - August 17 at 7:29 PM
News IconIntraday Active Biotech Stocks News: Relypsa, Inc. (NASDAQ:RLYP), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) - The Voice Registrar (NASDAQ:RLYP) - August 15 at 7:32 PM logoGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Relypsa, Inc. (RLYP) (NASDAQ:RLYP) - August 15 at 7:32 PM logoRELYPSA INC Financials (NASDAQ:RLYP) - August 12 at 7:15 PM logoAnalysts Ranking Activities: Relypsa, Inc. (NASDAQ:RLYP) , Akorn, Inc. (NASDAQ:AKRX) - Street Updates (NASDAQ:RLYP) - August 9 at 7:27 PM
News IconAnalyst's Estimates on Shares' Price: Relypsa Inc (NASDAQ:RLYP) - Post Registrar (NASDAQ:RLYP) - August 9 at 7:27 PM logoNew details reveal Relypsa is a hot commodity (NASDAQ:RLYP) - August 9 at 7:27 PM logoHighland Capital Management Reveals Investment In Relypsa (RLYP) (NASDAQ:RLYP) - August 9 at 10:23 AM
News IconHealthcare Stocks Flagged As Top Movers: Zoetis Inc. (NYSE:ZTS), Relypsa, Inc. (NASDAQ:RLYP) - TWN (NASDAQ:RLYP) - August 8 at 7:24 PM
News IconHC Stocks Newsbeat: Relypsa Inc (NASDAQ:RLYP), CVS Health Corp (NYSE:CVS) - share market updates (press release) (NASDAQ:RLYP) - August 8 at 11:55 AM logoProcess To Acquire Relypsa Inc (NASDAQ:RLYP) Kicks Off (NASDAQ:RLYP) - August 6 at 7:10 PM logoStocks Worth Mentioning Ratings-Wise: Relypsa Inc (NASDAQ:RLYP), Cooper Tire & Rubber Co (NYSE:CTB) - Review Fortune (NASDAQ:RLYP) - August 5 at 7:22 PM
News IconAnalyst Opinion Summary: Relypsa, Inc. (NASDAQ:RLYP), Intel Corporation (NASDAQ:INTC) - TWN (NASDAQ:RLYP) - August 5 at 7:22 PM logoCantor Reiterates Hold on Relypsa Inc (RLYP) Following 2Q:16 Results - Smarter Analyst (NASDAQ:RLYP) - August 5 at 7:22 PM logoAnalyst's Checklist Stocks: Sangamo BioSciences, Inc. (NASDAQ:SGMO) , Relypsa, Inc. (NASDAQ:RLYP) - Street Updates (NASDAQ:RLYP) - August 5 at 7:22 PM logoRELYPSA INC Files SEC form 10-Q, Quarterly Report (NASDAQ:RLYP) - August 4 at 7:39 PM logoRecent Analysts Ratings Fluctuations: Abbott Laboratories (NYSE:ABT) , Relypsa, Inc. (NASDAQ:RLYP) - Street Updates (NASDAQ:RLYP) - August 4 at 10:22 AM logoGalenica commences Tender Offer for Relypsa (NASDAQ:RLYP) - August 4 at 10:22 AM
News IconAnalyst Research and Recommendations: Relypsa, Inc. (NASDAQ:RLYP), Fossil Group, Inc. (NASDAQ:FOSL) - The Wellesleys News (NASDAQ:RLYP) - August 3 at 10:27 AM


Relypsa (NASDAQ:RLYP) Chart for Wednesday, October, 26, 2016

Last Updated on 10/26/2016 by Staff